NTNattaya Teeyapun

Nattaya Teeyapun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nattaya Teeyapun has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Data from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

    by Nussara Pakvisal, Piriya Wongkongkathep, Worawan Bunrasmee, Pimpayao Sodsai, Jirattha Siriluksana, Nittaya Boonnak, Tawanchay Sangcharoen, Bussaba Trakarnsanga, Shama Sukprakun, Peepattra Wantanasiri, et al.

    Purpose:To evaluate the safety and immunogenicity of intramuscularly delivered personalized neoantigen synthetic long peptide (SLP) vaccines in patients with advanced solid tumors. Patients and Methods:In this phase I trial, 12 patients with advanced melanoma (n = 9) or renal cell carcinoma (n = 3) who lacked access to further reimbursed standard therapies at enrollment received intramuscular neoantigen SLP vaccines with Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC). Each vaccine contained about 20 predicted neoantigen peptides. Adverse events were monitored throughout vaccination and follow-up. Immune profiling was performed at baseline and predefined postvaccination time points. Results:Intramuscular neoantigen vaccination was well tolerated, with only grade 1 to 2 local pain or fever and no immune-mediated toxicities. All participants developed de novo T-cell responses, which were detectable as early as 1 week after vaccination in most patients. On average, 53% of peptides per patient were immunogenic, inducing both CD8+ and CD4+ neoantigen-specific responses. Patients previously treated with immune checkpoint inhibitors (ICI) had higher baseline immunity but achieved comparable postvaccination responses to ICI-naïve patients. IFNγ-dominant CD8+ and TNFα-dominant CD4+ responses were observed, along with increased effector memory differentiation. Two patients with higher CD8+ terminal effector memory RA (TEMRA) proportions were the longest survivors. Tumor biopsies revealed enhanced CD8+ infiltration, and epitope spreading occurred in two evaluable cases. An analysis of 239 peptides showed greater immunogenicity for dual MHC I/II–binding, cysteine-containing, in-frame insertions or deletions–derived or low variant allele frequency–derived mutations, whereas proline substitutions reduced responses. Conclusions:Intramuscular neoantigen SLP vaccination with poly-ICLC is safe and induces rapid, mutation-specific T-cell immunity with robust CD8+ effector responses. These findings support intramuscular administration as a promising strategy for peptide-based cancer vaccines.

  • Open Access

    Supplementary Data 3 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

    by Nussara Pakvisal, Piriya Wongkongkathep, Worawan Bunrasmee, Pimpayao Sodsai, Jirattha Siriluksana, Nittaya Boonnak, Tawanchay Sangcharoen, Bussaba Trakarnsanga, Shama Sukprakun, Peepattra Wantanasiri, et al.

    Supplementary Data 3 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

  • Open Access

    Supplementary Data 5 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

    by Nussara Pakvisal, Piriya Wongkongkathep, Worawan Bunrasmee, Pimpayao Sodsai, Jirattha Siriluksana, Nittaya Boonnak, Tawanchay Sangcharoen, Bussaba Trakarnsanga, Shama Sukprakun, Peepattra Wantanasiri, et al.

    Supplementary Data 5 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

  • Open Access

    Supplementary Figures and Tables from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

    by Nussara Pakvisal, Piriya Wongkongkathep, Worawan Bunrasmee, Pimpayao Sodsai, Jirattha Siriluksana, Nittaya Boonnak, Tawanchay Sangcharoen, Bussaba Trakarnsanga, Shama Sukprakun, Peepattra Wantanasiri, et al.

    Supplementary Figures and Tables.

  • Open Access

    Supplementary Data 2 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

    by Nussara Pakvisal, Piriya Wongkongkathep, Worawan Bunrasmee, Pimpayao Sodsai, Jirattha Siriluksana, Nittaya Boonnak, Tawanchay Sangcharoen, Bussaba Trakarnsanga, Shama Sukprakun, Peepattra Wantanasiri, et al.

    Supplementary Data 2 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

  • Open Access

    Supplementary Data 4 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

    by Nussara Pakvisal, Piriya Wongkongkathep, Worawan Bunrasmee, Pimpayao Sodsai, Jirattha Siriluksana, Nittaya Boonnak, Tawanchay Sangcharoen, Bussaba Trakarnsanga, Shama Sukprakun, Peepattra Wantanasiri, et al.

    Supplementary Data 4 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

  • Open Access

    Supplementary Data 1 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

    by Nussara Pakvisal, Piriya Wongkongkathep, Worawan Bunrasmee, Pimpayao Sodsai, Jirattha Siriluksana, Nittaya Boonnak, Tawanchay Sangcharoen, Bussaba Trakarnsanga, Shama Sukprakun, Peepattra Wantanasiri, et al.

    Supplementary Data 1 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

  • Open Access

    Rare Gastroesophageal Tumor Subtypes: Clinicopathologic Characteristics, Molecular Alterations, and Therapeutic Implications

    by Fatemeh Sadat Tabatabaei, Nicholas J. Caldwell, Nattaya Teeyapun, Seyed Mohammad Amin Dashti, Sienna M. Durbin, Matthew Strickland, Jonathan N. Glickman, Samuel J. Klempner

    Rare subtypes of gastroesophageal malignancies represent a small but biologically meaningful fraction of upper gastrointestinal cancers. Although most therapeutic algorithms are derived from conventional squamous cell carcinoma and adenocarcinoma, uncommon entities such as variants of squamous cell carcinoma, lymphoepithelioma-like carcinoma, adenosquamous carcinoma, neuroendocrine carcinoma, and others display distinct clinicopathologic, immunologic, and molecular features that may influence prognosis and therapeutic decision-making. This review synthesizes current evidence regarding the epidemiology, histopathology, molecular alterations, and emerging therapeutic vulnerabilities across these rare subtypes. Importantly, these tumors frequently exhibit aggressive clinical behavior and are often managed by extrapolation from more common histologies due to the absence of prospective data. Increasing integration of genomic profiling, immune characterization, and biomarker-driven stratification is essential to refine diagnoses, expand precision therapeutic strategies, and improve outcomes. Recognition of these rare subtypes in routine practice is critical, as even small molecularly defined populations may carry disproportionate biological and translational significance within oncology.

  • The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

    by Nussara Pakvisal, Piriya Wongkongkathep, Worawan Bunrasmee, Pimpayao Sodsai, Jirattha Siriluksana, Nittaya Boonnak, Tawanchay Sangcharoen, Bussaba Trakarnsanga, Shama Sukprakun, Peepattra Wantanasiri, et al.

    Purpose: To evaluate the safety and immunogenicity of intramuscularly delivered personalized neoantigen synthetic long peptide (SLP) vaccines in patients with advanced solid tumors. Patients and Methods: In this phase I trial, 12 patients with advanced melanoma (n = 9) or renal cell carcinoma (n = 3) who lacked access to further reimbursed standard therapies at enrollment received intramuscular neoantigen SLP vaccines with Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC). Each vaccine contained about 20 predicted neoantigen peptides. Adverse events were monitored throughout vaccination and follow-up. Immune profiling was performed at baseline and predefined postvaccination time points. Results: Intramuscular neoantigen vaccination was well tolerated, with only grade 1 to 2 local pain or fever and no immune-mediated toxicities. All participants developed de novo T-cell responses, which were detectable as early as 1 week after vaccination in most patients. On average, 53% of peptides per patient were immunogenic, inducing both CD8+ and CD4+ neoantigen-specific responses. Patients previously treated with immune checkpoint inhibitors (ICI) had higher baseline immunity but achieved comparable postvaccination responses to ICI-naïve patients. IFNγ-dominant CD8+ and TNFα-dominant CD4+ responses were observed, along with increased effector memory differentiation. Two patients with higher CD8+ terminal effector memory RA (TEMRA) proportions were the longest survivors. Tumor biopsies revealed enhanced CD8+ infiltration, and epitope spreading occurred in two evaluable cases. An analysis of 239 peptides showed greater immunogenicity for dual MHC I/II–binding, cysteine-containing, in-frame insertions or deletions–derived or low variant allele frequency–derived mutations, whereas proline substitutions reduced responses. Conclusions: Intramuscular neoantigen SLP vaccination with poly-ICLC is safe and induces rapid, mutation-specific T-cell immunity with robust CD8+ effector responses. These findings support intramuscular administration as a promising strategy for peptide-based cancer vaccines.


  • Open Access

    Feasibility and Preliminary Effectiveness of the ChulaCancer Mobile Chatbot for Supportive Care of Patients With Breast or Colorectal Cancer Receiving Chemotherapy: Pilot Randomized Controlled Trial

    by Narawitch Sompornpailin, Thiti Susiriwatananont, Virote Sriuranpong, Suebpong Tanasanvimon, Chanida Vinayanuwattikun, Piyada Sitthideatphaiboon, Nattaya Poovorawan, Nattaya Teeyapun, Nicha Zungsontiporn, Nussara Pakvisal, et al.

    Background: Chemotherapy-related toxicities often lead to unscheduled health care use and diminished quality of life. Digital health interventions, such as chatbots, offer a scalable solution for supportive care; however, evidence regarding their effectiveness in resource-limited, low- and middle-income settings remains limited. Objective: This study aimed to evaluate the feasibility, use, and preliminary effectiveness of a closed-loop chatbot (ChulaCancer Chatbot) in reducing unscheduled hospital visits and stabilizing quality of life among patients receiving chemotherapy for breast or colorectal cancer. Methods: This pilot randomized controlled trial enrolled 40 patients at a single academic center in Thailand, randomized 1:1 to either ChulaCancer chatbot plus usual care or usual care alone. The primary end point was the proportion of unscheduled hospital visits due to chemotherapy-related toxicities within 12 weeks of treatment initiation. Secondary end points included longitudinal quality of life changes (30-item EORTC Quality of Life Questionnaire) measured at baseline, following chemotherapy cycle 2, and following cycle 4. Use metrics were extracted from the chatbot platform. Data were analyzed using the Fisher exact test and linear mixed-effects models. Results: The platform recorded 2393 total messages with a 70.5% (503/713) successful response rate for user-initiated queries. Unscheduled hospital visits occurred in 15% (3/20) of the chatbot group compared to 35% (7/20) of the usual care group (P=.24). While infection-related visits were similar between groups, the usual care group recorded multiple visits for low-acuity symptoms (eg, anxiety, headache, and edema) that were absent in the chatbot group. Regarding quality of life, the chatbot group demonstrated a significant mitigation of cancer-related fatigue following cycle 4 compared with the usual care group (P=.02 between groups). Additionally, the chatbot group significantly improved in global health status (P=.04) and avoided the decline in physical functioning observed in the control arm (P=.04). Conclusions: The integration of a closed-loop chatbot into oncology care is feasible and provides a potential secure triage mechanism that may reduce acute care use for low-acuity concerns. Future large-scale trials incorporating agentic artificial intelligence are warranted to further validate clinical and economic benefits. Trial Registration: Thai Clinical Trials Registry TCTR20251220014; https://tinyurl.com/5b6k3e63